This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2013 Aug;34(31):2426-8.

doi: 10.1093/eurheartj/eht235. Epub 2013 Jul 3.

The ARTS of third-generation mineralocorticoid receptor antagonists: achieving cardiovascular benefit with minimized renal side effects?

Johann Bauersachs

PMID: 23824829
DOI: 10.1093/eurheartj/eht235

Editorial

The ARTS of third-generation mineralocorticoid receptor antagonists: achieving cardiovascular benefit with minimized renal side effects?

Johann Bauersachs. Eur Heart J. 2013 Aug.

. 2013 Aug;34(31):2426-8.

doi: 10.1093/eurheartj/eht235. Epub 2013 Jul 3.

Author

Johann Bauersachs

PMID: 23824829
DOI: 10.1093/eurheartj/eht235

No abstract available

PubMed Disclaimer

Comment on

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial.
Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, Nowack C, Kolkhof P, Kim SY, Zannad F. Pitt B, et al. Eur Heart J. 2013 Aug;34(31):2453-63. doi: 10.1093/eurheartj/eht187. Epub 2013 May 27. Eur Heart J. 2013. PMID: 23713082 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Other Literature Sources
- scite Smart Citations